Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
21 December 2022 - 10:00PM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, will present at the
41st Annual J.P. Morgan Healthcare Conference in San Francisco,
California.
Axonics is scheduled to present at 4:30 p.m. Pacific Time on
Wednesday, January 11. A live webcast and archived replay of the
presentation will be accessible on the Axonics investor relations
website.
In advance of the presentation and scheduled investor meetings,
Axonics will issue a press release before the market opens on
January 11 that provides preliminary unaudited 2022 financial
results and initial 2023 financial guidance.
About Axonics®
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 1 on the
2022 Financial Times ranking of the 500 fastest growing companies
in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™
following its No. 1 ranking in 2021.
Axonics sacral neuromodulation (SNM) systems provide patients
suffering from overactive bladder and/or fecal incontinence with
long-lived, easy to use, safe, clinically effective therapy. In
addition, the company’s best-in-class urethral bulking hydrogel,
Bulkamid, provides safe and durable symptom relief to women with
stress urinary incontinence (SUI). Overactive bladder affects an
estimated 87 million adults in the U.S. and Europe, with an
additional 40 million adults estimated to suffer from fecal
incontinence. SUI affects an estimated 29 million women in the U.S.
alone. Axonics’ clinically proven products are offered at hundreds
of medical centers across the U.S. and abroad. Reimbursement
coverage is well established in the U.S. and is a covered service
in most European countries. For more information, visit
www.axonics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221221005008/en/
Axonics: Neil Bhalodkar 949-336-5293 ir@axonics.com
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Mar 2023 to Mar 2024